How Jupiter Neuroscience's Two-Prong Approach Could Crack The Code On Biotech SuccessSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
How Jupiter Neuroscience's Two-Prong Approach Could Crack The Code On Biotech SuccessDETROIT, MICHIGAN - June 16, 2025 ( NEWMEDIAWIRE ) - While being a biotech company can be difficult, it is not impossible. Just look at Jupiter Neurosciences Inc. (
NASDAQ: JUNS), a clinical-stage pharmaceutical company, for evidence. The company, which is developing drugs to treat neuroinflammation, with a current focus on central nervous system or CNS disorders such as Alzheimer's and Parkinson's and rare diseases, is taking a two-prong approach. That enables it to help people long-term and generate recurring revenue in the short-term.
Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVORLANDO, FL / ACCESS Newswire / March 7, 2025 / RedChip Companies will air interviews with Alliance Entertainment Holding Corp. (Nasdaq:AENT) and Jupiter Neurosciences, Inc. (Nasdaq:JUNS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, March 8, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
